References
- Tonelli AR, Lottenberg R, Allan RW, et al. Rituximab-induced hypersensitivity pneumonitis. Respiration 2009;78:225–229.
- Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 2012;19:32–38.
- Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008;20:332–338.
- Stalika E, Papalexandri A, Kannelis G, et al. Transient monoclonal CD3 + T large granular lymphocyte proliferation in a case of mantle cell lymphoma with rituximab-associated late onset neutropenia. Hematol Oncol 2011;29:144–146.
- Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 2008;22:1446–1449.
- Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002;26: 597–600.
- Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690–2691.
- Lee Y, Kyung SY, Choi SJ, et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006;21:183–186.
- van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
- Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev 2010;10:236–247.
- Lund FE, Garvy BA, Randall TD, et al. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Direct Autoimmun 2005;8:25–54.
- Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 2008;127:280–285.
- Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J allergy Clin Immunol 2008;121:13–21.
- Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy--rare but there!Leuk Lymphoma 2009; 50:1083–1095.
- Minutello MA, Pileri P, Unutmaz D, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993;178:17–25.
- Douglas VK, Gordon LI, Goolsby CL, et al. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma. Am J Clin Pathol 1999;112: 844–853.